About
Sight-threatening Diseases
Areas of Focus
Categories
Biologics & BiopharmaceuticalNJ, NY, PA
Clinical Trials (12)
View allTotal Trials
12
As Lead Sponsor
11
As Collaborator
1
Total Enrollment
1,123
By Phase
PHASE3: 3PHASE1: 1PHASE2/PHASE3: 2PHASE1/PHASE2: 3PHASE2: 1
By Status
RECRUITING: 3ACTIVE_NOT_RECRUITING: 2TERMINATED: 2COMPLETED: 2UNKNOWN: 1NO_LONGER_AVAILABLE: 1AVAILABLE: 1
Clinical Trials Pipeline10 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT06388200Lead Sponsor
A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa
PHASE3Recruiting
150 participants
Started: Jun 18, 2024 · Completed: Dec 31, 2026
NCT05802329Lead Sponsor
Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)
PHASE1Recruiting
30 participants
Started: Jan 13, 2024 · Completed: Jul 31, 2026
NCT05956626Lead Sponsor
A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease
PHASE2/PHASE3Recruiting
51 participants
Started: Aug 25, 2023 · Completed: Sep 28, 2026
NCT06018558Lead Sponsor
Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy
PHASE1/PHASE2Active, not recruiting
60 participants
Started: Feb 23, 2023 · Completed: May 29, 2026
NCT05258669Lead Sponsor
Immuno-bridging and Broadening Study of a Whole, Inactivated COVID-19 Vaccine BBV152 in Healthy Adults
PHASE2/PHASE3Unknown
400 participants
Started: Feb 20, 2022 · Completed: Oct 31, 2023
Locations (1)
Headquarters
Malvern, PA, United States
Map
Loading map...